AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16219630 — intervention group
Group type: EXPERIMENTAL
Intervention: School Fruit Programme (no parental cost)
Number of subjects: 517
Study 16219630 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 517
Study 12668820 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-surgery stapled haemorrhoidectomy
Number of subjects: 48
Study 12668820 — intervention group
Group type: COMPARATOR
Intervention: In-patient stapled haemorrhoidectomy
Number of subjects: 48
Study 12668820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Day-surgery and In-patient)
Number of subjects: 48
Study 10750210 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of absolute cardiovascular risk by general practitioners and practice nurses
Number of subjects: 0
Study 9041463 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IFN, 6 x 10(6) U/m2 daily x 3 every 4 weeks
Number of subjects: 71
Study 9041463 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IFN, 12 x 10(6) U/m2, 3 x/week
Number of subjects: 71
Study 9041463 — intervention group
Group type: EXPERIMENTAL
Intervention: Both low-dose and high-dose IFN
Number of subjects: 71
Study 9041463 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IFN
Number of subjects: 71
Study 9041463 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving >= 6 weeks of therapy
Number of subjects: 71
Study 9041463 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response to IFN
Number of subjects: 71
Study 1424422 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg/day)
Number of subjects: 2
Study 1424422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 6366561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (60 mg per day)
Number of subjects: 10
Study 6366561 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg per day)
Number of subjects: 10
Study 6366561 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg per day)
Number of subjects: 10
Study 6366561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31018810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency right-sided repetitive transcranial magnetic stimulation (LFR rTMS) over the right dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 30
Study 31018810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency right-sided repetitive transcranial magnetic stimulation (LFR rTMS)
Number of subjects: 30
Study 31018810 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study 28329789 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (Med diet)
Number of subjects: 20
Study 28329789 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with Coenzyme Q10 (Med + CoQ)
Number of subjects: 20
Study 28329789 — intervention group
Group type: COMPARATOR
Intervention: Western high-saturated-fat diet (SFA diet)
Number of subjects: 20
Study 27430920 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS‐GS‐TBLB with VBN
Number of subjects: 184
Study 27430920 — intervention group
Group type: COMPARATOR
Intervention: EBUS‐GS‐TBLB without VBN
Number of subjects: 184
Study 25034547 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (9 to 5 X 1000 m)
Number of subjects: 24
Study 25034547 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous training (9000 to 5000 m)
Number of subjects: 24
Study 22573431 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (400 IU/day) and Calcium (1,000 mg elemental)
Number of subjects: 36282
Study 22573431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study 20147467 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable portion size increased (180, 270, or 360 g)
Number of subjects: 97
Study 20147467 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution of vegetable for grain and meat
Number of subjects: 97
Study 20147467 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in vegetable energy density (0.8 or 0.4 kcal/g)
Number of subjects: 97
Study 20147467 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of substitution and reduction in energy density
Number of subjects: 97
Study 18949299 — intervention group
Group type: COMPARATOR
Intervention: No preflaring (Group 1)
Number of subjects: 50
Study 18949299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical preflaring with LA Axxess burs (Group 5)
Number of subjects: 50
Study 18949299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical preflaring with EndoFlare instruments (Group 4)
Number of subjects: 50
Study 18949299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical preflaring with Gates‐Glidden drills (Group 2)
Number of subjects: 50
Study 18949299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical preflaring with ProTaper instruments (Group 3)
Number of subjects: 50
Study 15793271 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication group watching a videotape about communicating and managing postoperative pain
Number of subjects: 38
Study 15793271 — intervention group
Group type: COMPARATOR
Intervention: Comparison group watching a videotape about managing postoperative pain only
Number of subjects: 38
Study 15793271 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication group
Number of subjects: 38
Study 12395916 — intervention group
Group type: EXPERIMENTAL
Intervention: Pueraria thomsonii dried flower extracts
Number of subjects: 0
Study 12395916 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 10066201 — intervention group
Group type: EXPERIMENTAL
Intervention: One neonatal screening examination (one screen policy)
Number of subjects: 9712
Study 10066201 — intervention group
Group type: COMPARATOR
Intervention: Two neonatal screening examinations (two screen policy)
Number of subjects: 9712
Study 7738889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 67
Study 7738889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cholangiography (IVC)
Number of subjects: 67
Study 7738889 — intervention group
Group type: COMPARATOR
Intervention: Comparison of US and IVC
Number of subjects: 67
Study 1917621 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment time within 49 days (≤ 7 weeks)
Number of subjects: 780
Study 1917621 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment time 50 to 63 days (8 to 9 weeks)
Number of subjects: 780
Study 1917621 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment time ≥ 64 days (> 9 weeks)
Number of subjects: 780
Study 1917621 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason scores 2-5
Number of subjects: 780
Study 1917621 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason scores 6-7
Number of subjects: 780
Study 1917621 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason scores 8-10
Number of subjects: 780
Study 1917621 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of late complications
Number of subjects: 780
Study 7470200 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 5
Study 30900733 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anterior and posterior 2‐segment spinal fusion
Number of subjects: 27
Study 30900733 — intervention group
Group type: COMPARATOR
Intervention: Posterior 3‐segment spinal fusion
Number of subjects: 27
Study 28490557 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin
Number of subjects: 34
Study 28490557 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 25668435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration (24 IU)
Number of subjects: 66
Study 25132201 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg
Number of subjects: 70
Study 25132201 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 70
Study 22968100 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fast-food meal (hamburger meal, glycemic load = 48.7)
Number of subjects: 25
Study 22968100 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconventional fast-food meal (salmonburger meal, glycemic load = 46.0)
Number of subjects: 25
Study 19336851 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% amitriptyline gel
Number of subjects: 56
Study 19336851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 17417723 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded cardiac rehabilitation
Number of subjects: 224
Study 17417723 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation
Number of subjects: 224
Study 15021286 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioject jet injector
Number of subjects: 40
Study 15021286 — intervention group
Group type: COMPARATOR
Intervention: 25G needle injection
Number of subjects: 40
Study 11685307 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support of 10 cmH2O
Number of subjects: 257
Study 11685307 — intervention group
Group type: COMPARATOR
Intervention: T‐piece
Number of subjects: 257
Study 9673757 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 9673757 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7521559 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific reading retardation group (n = 37)
Number of subjects: 399
Study 7521559 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal intelligence (n = 285)
Number of subjects: 399
Study 2510329 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin 400 mg
Number of subjects: 152
Study 2510329 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg IM
Number of subjects: 152
Study 2510329 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin
Number of subjects: 152
Study 2510329 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 152
Study 2510329 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin and Ceftriaxone
Number of subjects: 152
Study 941915 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 82
Study 941915 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephapirin
Number of subjects: 82
Study 941915 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp vein needles
Number of subjects: 82
Study 941915 — intervention group
Group type: COMPARATOR
Intervention: Plastic catheters
Number of subjects: 82
Study 31025385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafine granular powder (UGP)
Number of subjects: 0
Study 31025385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafine powder (UP)
Number of subjects: 0
Study 31025385 — intervention group
Group type: COMPARATOR
Intervention: Traditional decoction pieces (TDP)
Number of subjects: 0
Study 28984772 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: fluid‐air exchange tube connected to a 1 mL syringe with the plunger removed and the tip dilated with a hemostat.
Number of subjects: 86
Study 28984772 — intervention group
Group type: COMPARATOR
Intervention: Group B: tip of the syringe closely attached to the cap of the 23‐gauge cannula by a tube adaptor.
Number of subjects: 86
Study 25567410 — intervention group
Group type: EXPERIMENTAL
Intervention: Local mild hypothermia with conventional mannitol (Group A)
Number of subjects: 36
Study 25567410 — intervention group
Group type: COMPARATOR
Intervention: Conventional mannitol (Group B)
Number of subjects: 36
Study 23699977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab, 0.5 mg
Number of subjects: 789
Study 23699977 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 789
Study 23699977 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity improvement
Number of subjects: 789
Study 21168116 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong training for half an hour daily for six weeks
Number of subjects: 37
Study 21168116 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Qigong training during the first six weeks)
Number of subjects: 37
Study 19066368 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU every other day)
Number of subjects: 14641
Study 19066368 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg daily)
Number of subjects: 14641
Study 17122713 — intervention group
Group type: EXPERIMENTAL
Intervention: Unannounced standardized patients (SPs)
Number of subjects: 242
Study 15015606 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic stenting
Number of subjects: 22
Study 15015606 — intervention group
Group type: COMPARATOR
Intervention: Colostomy
Number of subjects: 22
Study 11409458 — intervention group
Group type: EXPERIMENTAL
Intervention: Short anatomic femoral stem
Number of subjects: 24
Study 11409458 — intervention group
Group type: COMPARATOR
Intervention: Control side (contralateral side)
Number of subjects: 24
Study 9759611 — intervention group
Group type: EXPERIMENTAL
Intervention: GPIIb/IIIa‐inhibitor MK383
Number of subjects: 0
Study 9759611 — intervention group
Group type: COMPARATOR
Intervention: Heparin (0.2 U/ml)
Number of subjects: 0
Study 7886407 — intervention group
Group type: COMPARATOR
Intervention: Furosemide with placebo pre-treatment
Number of subjects: 0
Study 7886407 — intervention group
Group type: COMPARATOR
Intervention: Furosemide with captopril pre-treatment
Number of subjects: 0
Study 7886407 — intervention group
Group type: COMPARATOR
Intervention: Furosemide with prazosin pre-treatment
Number of subjects: 0
Study 3229117 — intervention group
Group type: EXPERIMENTAL
Intervention: Small doses of heparin (2 X 5000 u. subcutaneously/24 h)
Number of subjects: 408
Study 3229117 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (dorsal and plantar flexion of the foot for one minute each hour)
Number of subjects: 408
Study 3229117 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 408
Study 31950229 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec 200 U/ml (degludec U200)
Number of subjects: 1609
Study 31950229 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 300 U/ml (glargine U300)
Number of subjects: 1609
Study 30497483 — intervention group
Group type: EXPERIMENTAL
Intervention: Chuna manual therapy (10 sessions, twice a week for 5 weeks)
Number of subjects: 108
Study 30497483 — intervention group
Group type: COMPARATOR
Intervention: Usual care (conventional physical therapy and medication treatment)
Number of subjects: 108
Study 30497483 — intervention group
Group type: EXPERIMENTAL
Intervention: Chuna manual therapy
Number of subjects: 108
Study 30497483 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study 28026713 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intervention (ModTx)
Number of subjects: 78
Study 28026713 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervention (StnTx)
Number of subjects: 78
Study 28026713 — intervention group
Group type: COMPARATOR
Intervention: Control (Ctrl)
Number of subjects: 78
Study 25155416 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid infusion into the distal esophagus
Number of subjects: 0
Study 25155416 — intervention group
Group type: COMPARATOR
Intervention: Control infusion
Number of subjects: 0
Study 22921577 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate referral for colposcopy
Number of subjects: 2213
Study 22921577 — intervention group
Group type: EXPERIMENTAL
Intervention: Not in paid employment
Number of subjects: 2213
Study 22921577 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 2213
Study 22921577 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age and level of post-school education/training
Number of subjects: 2213
Study 22921577 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with children
Number of subjects: 2213
Study 22921577 — intervention group
Group type: EXPERIMENTAL
Intervention: Not worried about having cervical cancer
Number of subjects: 2213
Study 22921577 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and depression
Number of subjects: 2213
Study 20377145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal scopolamine (0.4 mg)
Number of subjects: 16
Study 20377145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20377145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal scopolamine
Number of subjects: 16
Study 18296328 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg L-theanine
Number of subjects: 35
Study 18296328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 15642700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (titrated from 1.25 mg once daily to 10 mg once daily, mean maintenance dose 7.7 mg)
Number of subjects: 2128
Study 15642700 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mean maintenance dose 8.5 mg)
Number of subjects: 2128
Study 15642700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 2128
Study 15642700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2128
Study 12784841 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (mean blood alcohol concentration of .10)
Number of subjects: 40
Study 12784841 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 40
Study 11111630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle strengthening and walking program (3-month supervised)
Number of subjects: 16
Study 11111630 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study 9288412 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of haloperidol
Number of subjects: 40
Study 9288412 — intervention group
Group type: COMPARATOR
Intervention: 0.7 degree C‐increase in body core temperature due to 3‐h exposure to an ambient temperature of 52 degrees C
Number of subjects: 40
Study 8327802 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 0
Study 8327802 — intervention group
Group type: COMPARATOR
Intervention: Treatment B
Number of subjects: 0
Study 3525768 — intervention group
Group type: EXPERIMENTAL
Intervention: VMCP-VBAP without levamisole
Number of subjects: 440
Study 29170792 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% prilocaine/lidocaine (EMLA) cream
Number of subjects: 120
Study 29170792 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin suppository
Number of subjects: 120
Study 29170792 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 120
Study 29170792 — intervention group
Group type: COMPARATOR
Intervention: Placebo (simple lubrication)
Number of subjects: 120
Study 27335234 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic simple enucleation (Group 1)
Number of subjects: 40
Study 27335234 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic enucleation-separation (Group 2)
Number of subjects: 40
Study 27335234 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 40
Study 25680360 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy users
Number of subjects: 482
Study 25680360 — intervention group
Group type: COMPARATOR
Intervention: Medication only users
Number of subjects: 482
Study 25680360 — intervention group
Group type: COMPARATOR
Intervention: Participants not utilizing medications or psychotherapy
Number of subjects: 482
Study 23690342 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker treatment
Number of subjects: 1345
Study 20427734 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (45 mg zinc/d as gluconate for 6 months)
Number of subjects: 40
Study 20427734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18987396 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hemostasis patch (SafeSeal Patch, Possis Medical Inc.) with manual pressure
Number of subjects: 150
Study 18987396 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual pressure alone
Number of subjects: 150
Study 18987396 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 16635793 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (THY) 4.5 to 6.0 mg/kg
Number of subjects: 56
Study 16635793 — intervention group
Group type: COMPARATOR
Intervention: Targeted busulfan/cyclophosphamide (BUCY) without THY
Number of subjects: 56
Study 12825855 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg as a monthly intramuscular injection followed by subsequent endocrine therapy
Number of subjects: 423
Study 12825855 — intervention group
Group type: COMPARATOR
Intervention: Subsequent endocrine therapy after no clinical benefit from fulvestrant
Number of subjects: 423
Study 11023930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of 5 mg of P5 variant
Number of subjects: 29
Study 11023930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of 2.5 mg of P10 variant
Number of subjects: 29
Study 11023930 — intervention group
Group type: EXPERIMENTAL
Intervention: P5, P10, P20 variants
Number of subjects: 29
Study 11023930 — intervention group
Group type: COMPARATOR
Intervention: SakSTAR
Number of subjects: 29
Study 8828024 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10mg once daily
Number of subjects: 0
Study 8828024 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60mg twice daily
Number of subjects: 0
Study 8828024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31204332 — intervention group
Group type: EXPERIMENTAL
Intervention: Charcoal infused bristle toothbrushes (T1)
Number of subjects: 25
Study 31204332 — intervention group
Group type: COMPARATOR
Intervention: Nylon bristle toothbrushes (T2)
Number of subjects: 25
Study 29939261 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh amaranth forage (FAF)
Number of subjects: 6
Study 29939261 — intervention group
Group type: COMPARATOR
Intervention: Ensiled amaranth without additive (EA)
Number of subjects: 6
Study 29939261 — intervention group
Group type: EXPERIMENTAL
Intervention: EA + 5% of molasses (EAM)
Number of subjects: 6
Study 29939261 — intervention group
Group type: EXPERIMENTAL
Intervention: EA inoculated with LAB (EAB)
Number of subjects: 6